

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com

 Web:
 lktlabs.com

Product Information


Product ID M0374

CAS No. 790299-79-5

Chemical Name 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide

Synonym AB1010; Masatinib; Masitinib (AB1010); Masivet

Formula C₂₈H₃₀N₆OS Formula Wt. 498.64 Melting Point Purity ≥98% Solubility



Bulk quanitites available upon request

Product ID	Size
M0374	5 mg
M0374	25 mg
M0374	100 mg

Store Temp Ambient

Ship Temp Ambient

Description Masitinib is an anticancer chemotherapeutic and anti-inflammatory compound used in veterinary medicine. Masitinib inhibits c-Kit and PDGFR, increasing survival time in the treatment of mast cell tumors and other cancers. In vitro, masitinib increases levels of caspases 3 and 7, inducing apoptosis. Masitinib also decreases airway inflammation and edema in feline allergic asthma models and also decreases the patient-rated severity of multiple sclerosis in clinical settings. Masitinib also exhibits potential efficacy against Alzheimer's disease when given as an adjunct therapy, slowing cognitive decline.

References Smrkovski OA, Essick L, Rohrbach BW, et al. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Vet Comp Oncol. 2013 Jul 12. [Epub ahead of print]. PMID: 23845124.

Fahey CE, Milner RJ, Kow K, et al. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anticancer Drugs. 2013 Jun;24(5):519-26. PMID: 23466652.

Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012 Jun 12;12:36. PMID: 22691628.

Lee-Fowler TM, Guntur V, Dodam J, et al. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158(4):369-74. PMID: 22487554.

Cadot P, Hensel P, Bensignor E, et al. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, doubleblind, placebo-controlled phase 3 trial. Vet Dermatol. 2011 Dec;22(6):554-64. PMID: 21668810.

Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011 Apr 19;3(2):16. PMID: 21504563.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.